News

Population data from Greater Manchester show Black, Asian, and mixed-ethnicity patients with lupus receive greater oral corticosteroid doses.

The approval adds brepocitinib (Lisraya), an oral JAK/TYK2 inhibitor, as the first agent specifically studied and approved for dermatomyositis in adults.

Baseline structural damage accounted for most of the variance in placebo-arm radiographic progression across 6 PsA trials.

Garetosmab-grts is the first treatment demonstrating reduced new heterotopic ossification lesions and flare-ups in adults with FOP.

Efgartigimod produced significant, sustained improvement in autoimmune myositis, including the first positive phase 3 results in IMNM.

Woodrick discusses how his team monitors subclinical progression and the multidisciplinary consortium supporting care.

Ruderman discusses how Northwestern's joint dermatology-rheumatology clinic shapes diagnosis and treatment of psoriatic disease.

Sonelokimab hit its primary ACR50 endpoint and all key secondary endpoints in biologic-naive patients with psoriatic arthritis in the phase 3 IZAR-1 trial.

In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.

Mease revisits the biggest PsA readouts from EULAR 2026: guselkumab, izokibep, GLP-1 combo therapy and more.

Richardson discusses the safety profile of CD19 CAR-T, the debate over B cell targets, and more.

Carrie Richardson, MD, discusses what early CAR-T trial data mean for reversing damage and redefining remission in systemic sclerosis.

Baricitinib achieved glucocorticoid-free remission in 65% of patients with new-onset polymyalgia rheumatica at week 16, versus 17% with placebo.

A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.

Marta Mosca, MD, PhD, highlighted a 43.0% DORIS rate and a 74.1% LLDAS rate during the 12-month follow-up period with anifrolumab.

A post-hoc of 5 phase 3 trials saw non-glucocorticoid DORIS remission and LLDAS attainment nearly doubled vs placebo at week 52.

3-month topline data showed a 72% reduction in pain and a 109% improvement in function versus placebo, both exceeding prespecified FDA thresholds for Phase III advancement.

We're anticipating FDA decisions for tildrakizumab, obinutuzumab, and more, including a potential first targeted therapy for Sjögren's disease.

We reviewed new psoriatic arthritis approvals as well as data readouts from head-to-head trials and milestone data in IgG4-related disease.

Oral TLR7/8 inhibitor enpatoran earns FDA Breakthrough status for lupus skin disease, with Phase 2 CLASI-A gains and Phase 3 underway.

Findings from an independent, blinded re-adjudication of ADVOCATE's primary endpoints will be presented at an FDA hearing scheduled for July 2026.

With structural inhibition now in the label, Mease explains why radiographic protection matters as a treatment goal and what it means to have that evidence for an IL-23 inhibitor.

Key changes in the 2026 ACR/SAA/SPARTAN guideline update elevate JAK inhibitors to a strong recommendation and introduce nociplastic pain guidance.

Emanuel Della-Torre, MD, PhD, discusses the largest randomized controlled trial in IgG4-RD establishing proof of concept for B-cell inhibition.

Iain McInnes, MD, PhD, discussed comparing bimekizumab and risankizumab for PsA.

In the FIBRONEER-ILD autoimmune ILD subgroup, nerandomilast attenuated FVC decline and nominally reduced all-cause mortality risk at both doses.

Philip Mease, MD, discusses BE BOLD, which delivers the first head-to-head superiority result for a joint-focused endpoint in psoriatic arthritis.

Richard Furie, MD, discusses phase 2 JASMINE data showing sustained SRI-4 and LLDAS responses through 52 weeks.

Anisha Dua, MD, MPH, discusses the largest US real-world cohort to date in GPA/MPA.

Phase 2b/3 data show durable ACR50/70, PASI90/100, and minimal disease activity responses with izokibep through one year.